Dayan Gustavo H, Quinlisk M Patricia, Parker Amy A, Barskey Albert E, Harris Meghan L, Schwartz Jennifer M Hill, Hunt Kae, Finley Carol G, Leschinsky Dennis P, O'Keefe Anne L, Clayton Joshua, Kightlinger Lon K, Dietle Eden G, Berg Jeffrey, Kenyon Cynthia L, Goldstein Susan T, Stokley Shannon K, Redd Susan B, Rota Paul A, Rota Jennifer, Bi Daoling, Roush Sandra W, Bridges Carolyn B, Santibanez Tammy A, Parashar Umesh, Bellini William J, Seward Jane F
Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.
N Engl J Med. 2008 Apr 10;358(15):1580-9. doi: 10.1056/NEJMoa0706589.
BACKGROUND: The widespread use of a second dose of mumps vaccine among U.S. schoolchildren beginning in 1990 was followed by historically low reports of mumps cases. A 2010 elimination goal was established, but in 2006 the largest mumps outbreak in two decades occurred in the United States. METHODS: We examined national data on mumps cases reported during 2006, detailed case data from the most highly affected states, and vaccination-coverage data from three nationwide surveys. RESULTS: A total of 6584 cases of mumps were reported in 2006, with 76% occurring between March and May. There were 85 hospitalizations, but no deaths were reported; 85% of patients lived in eight contiguous midwestern states. The national incidence of mumps was 2.2 per 100,000, with the highest incidence among persons 18 to 24 years of age (an incidence 3.7 times that of all other age groups combined). In a subgroup analysis, 83% of these patients reported current college attendance. Among patients in eight highly affected states with known vaccination status, 63% overall and 84% between the ages of 18 and 24 years had received two doses of mumps vaccine. For the 12 years preceding the outbreak, national coverage of one-dose mumps vaccination among preschoolers was 89% or more nationwide and 86% or more in highly affected states. In 2006, the national two-dose coverage among adolescents was 87%, the highest in U.S. history. CONCLUSIONS: Despite a high coverage rate with two doses of mumps-containing vaccine, a large mumps outbreak occurred, characterized by two-dose vaccine failure, particularly among midwestern college-age adults who probably received the second dose as schoolchildren. A more effective mumps vaccine or changes in vaccine policy may be needed to avert future outbreaks and achieve the elimination of mumps.
背景:自1990年起,美国学童中广泛接种第二剂腮腺炎疫苗,随后腮腺炎病例报告数量处于历史低位。2010年设定了消除腮腺炎的目标,但2006年美国发生了二十年来最大规模的腮腺炎疫情。 方法:我们研究了2006年报告的全国腮腺炎病例数据、受影响最严重州的详细病例数据以及三项全国性调查的疫苗接种覆盖率数据。 结果:2006年共报告6584例腮腺炎病例,其中76%发生在3月至5月之间。有85例住院治疗,但无死亡报告;85%的患者居住在中西部八个相邻州。全国腮腺炎发病率为每10万人中2.2例,18至24岁人群发病率最高(发病率是所有其他年龄组总和的3.7倍)。在亚组分析中,这些患者中有83%报告目前正在上大学。在已知疫苗接种状况的八个受影响严重州的患者中,总体上63%以及年龄在18至24岁之间的患者中有84%接种了两剂腮腺炎疫苗。在疫情爆发前的12年里,全国学龄前儿童一剂腮腺炎疫苗接种覆盖率在全国范围内为89%或更高,在受影响严重的州为86%或更高。2006年,青少年两剂疫苗接种覆盖率为87%,为美国历史最高水平。 结论:尽管含腮腺炎疫苗两剂接种率很高,但仍发生了大规模腮腺炎疫情爆发,其特点是两剂疫苗接种失败,特别是在中西部大学年龄成年人中,他们很可能在儿童时期接种了第二剂疫苗。可能需要一种更有效的腮腺炎疫苗或改变疫苗政策,以避免未来疫情爆发并实现消除腮腺炎的目标。
N Engl J Med. 2008-4-10
Pediatr Infect Dis J. 2010-8
Pediatr Infect Dis J. 2008-10
Epidemiol Infect. 2011-4-20
MMWR Morb Mortal Wkly Rep. 2010-2-12
Pediatrics. 2007-10
Infect Dis Model. 2025-6-30
Commun Med (Lond). 2025-3-24
Vaccine. 2024-11-14
Vaccines (Basel). 2024-5-10
Virus Genes. 2023-8